Abstract
Calprotectin, a protein composed by two subunits of 8 and 14 kD respectively, is released by neutrophils in the biological fluids under inflammatory states. For instance, detection of calprotectin in faeces represents a diagnostic tool in the case of inflammatory bowel disease. Quite interestingly, calprotectin is increased in the stool of healthy newborns from day three up to day thirty and, physiologically, this increase may be interpreted as a defense mechanism against yeast and fungi. Therapeutic attempts at inhibiting the deleterious effect of calprotectin have been experimentally made by using lycoricinidol. This natural compound is able to hamper the calprotectin-induced apoptosis on the one hand. On the other hand, the same compound plays a prophylactic role in the course of experimental arthritis in rats.
Keywords: Calprotectin, inflammatory bowel disease, newborns, lycoricidinol
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Does Calprotectin Represent a Regulatory Factor in Host Defense or a Drug Target in Inflammatory Disease?
Volume: 7 Issue: 1
Author(s): M. E. Baldassarre, M. A. Altomare, M. Fanelli, D. Carbone, G. Di Bitonto, A. Mautone and N. Laforgia
Affiliation:
Keywords: Calprotectin, inflammatory bowel disease, newborns, lycoricidinol
Abstract: Calprotectin, a protein composed by two subunits of 8 and 14 kD respectively, is released by neutrophils in the biological fluids under inflammatory states. For instance, detection of calprotectin in faeces represents a diagnostic tool in the case of inflammatory bowel disease. Quite interestingly, calprotectin is increased in the stool of healthy newborns from day three up to day thirty and, physiologically, this increase may be interpreted as a defense mechanism against yeast and fungi. Therapeutic attempts at inhibiting the deleterious effect of calprotectin have been experimentally made by using lycoricinidol. This natural compound is able to hamper the calprotectin-induced apoptosis on the one hand. On the other hand, the same compound plays a prophylactic role in the course of experimental arthritis in rats.
Export Options
About this article
Cite this article as:
Baldassarre E. M., Altomare A. M., Fanelli M., Carbone D., Di Bitonto G., Mautone A. and Laforgia N., Does Calprotectin Represent a Regulatory Factor in Host Defense or a Drug Target in Inflammatory Disease?, Endocrine, Metabolic & Immune Disorders - Drug Targets 2007; 7 (1) . https://dx.doi.org/10.2174/187153007780059441
DOI https://dx.doi.org/10.2174/187153007780059441 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Degradation by the Ubiquitin-Proteasome Pathway and Organ Fibrosis
Current Medicinal Chemistry SNP Web Resources and Their Potential Applications in Personalized Medicine
Current Drug Metabolism Stem Cell-Derived Microvesicles: A Cell Free Therapy Approach to the Regenerative Medicine
Current Biotechnology Anti-Angiogenic Targets in the Treatment of Advanced Renal Cell Carcinoma
Current Cancer Drug Targets Application of Nanotechnology in the Treatment and Diagnosis of Gastrointestinal Cancers: Review of Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Boronic Acid-based Enzyme Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
Current Medicinal Chemistry Targeting the Epidermal Growth Factor Pathway as Therapy for Glioblastoma
Current Cancer Therapy Reviews Angiogenesis and Hypoxia in Glioblastoma: A Focus on Cancer Stem Cells
CNS & Neurological Disorders - Drug Targets Variances in the Level of COX-2 and iNOS in Different Grades of Endometrial Cancer
Current Pharmaceutical Biotechnology Src Family Kinases as Regulators of Angiogenesis: Therapeutic Implications
Current Cancer Therapy Reviews Smad-Signaling in Mammary Gland Development and Tumorigenesis
Current Signal Transduction Therapy Sorafenib (BAY 43-9006): Review of Clinical Development
Current Clinical Pharmacology The Need for Improvement of the Treatment of Advanced and Metastatic Cervical Cancer, the Rationale for Combined Chemo-Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy
Current Pharmaceutical Design Immune Responses to Fungal Infections and Therapeutic Implications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy
Current Topics in Medicinal Chemistry The Molecular Mechanisms of TRAIL Resistance in Cancer Cells: Help in Designing New Drugs
Current Pharmaceutical Design Fibroblast Growth Factor-Inducible 14: Multiple Roles in Tumor Metastasis
Current Molecular Medicine Estrogens and Colorectal Cancer
Current Drug Targets - Immune, Endocrine & Metabolic Disorders